On June 22, Eli Lilly and Company (NYSE:LLY) announced new results for its once-weekly insulin, Efsitora alfa. The drug is ...

Thursday, Eli Lilly and Company (NYSE:LLY) released topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in ...

In a Phase 3 study, Eli Lilly’s tirzepatide led to a 94% reduction in the risk that obese or overweight prediabetes patients progress to type 2 diabetes. Lilly was already planning to expand use ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker announced Thursday.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss. Latest U.S.

Eli Lilly says it plans to apply for approval for weight management by the end of this year, and for type 2 diabetes in 2026. If approved, it could be a game-changer for people who need a simpler ...

Eli Lilly daily diabetes pill could be as effective as Ozempic and Mounjaro, trial finds BY Susan Carpenter Nationwide PUBLISHED 1:00 PM ET Apr. 17, 2025 PUBLISHED 1:00 PM EDT Apr. 17, 2025 ...

By Robb M. Stewart. Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but are at risk for developing conditions such as diabetes.

Thursday, Eli Lilly and Company (NYSE:LLY) released topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in ...